Address
Manfred Eigen Campus
Essener Bogen 7
Hamburg
22419, Germany
Contact
Danielle Nind+4407874865873
danielle.nind@evotec.com
Website
Hollow Fibre Infection Model
Rapidly expanding facilities for in vitro PK/PD analysis in the Hollow Fibre Infection Model in BSL2
Longer study time periods leads to understanding the PK/PD relationships and the risks of the emergence of resistance in response to a given treatment
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compound/strategy
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Research
- Development
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- Co-develop
- Outsource
- Joint Venture
- License
- Sell
Funding organisation:
- CARB-X
- GARDP
- REPAIR
- FIND
- OTHER / NA
Infectious disease area:
- UTI
- STI
- BSI
- RTI
- GII
- SSTI
- CNSI
- IAI
- SSI
Geographic origin:
- Eurasia
- North America
- South America
- Africa
- Oceania
N.A.
Life science company providing access to highly effective new therapeutics, leveraging its multimodality platform with unique innovative technologies
BSL3 high throughput screening capabilities, up to 400,000 compounds, against numerous pathogens including Mycobacterium tuberculosis.
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!